<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>As <z:mpath ids='MPATH_3'>apoptosis</z:mpath> occurs over an interval of time after administration of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing therapy in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, the changes in <z:chebi fb="1" ids="33353">technetium</z:chebi> 99m ((99m)Tc)-tricarbonyl (CO)₃ His-annexin A5 (His-ann A5) accumulation over time were examined </plain></SENT>
<SENT sid="1" pm="."><plain>Colo205-bearing mice were divided into six treatment groups: (1) control, (2) <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU; 250 mg/kg), (3) irinotecan (100 mg/kg), (4) <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (30 mg/kg), (5) bevacizumab (5 mg/kg), and (6) panitumumab (6 mg/kg) </plain></SENT>
<SENT sid="2" pm="."><plain>(99m)Tc-(CO)₃ His-ann A5 was injected 4, 8, 12, 24, and 48 hours posttreatment, and micro-single-<z:chebi fb="23" ids="30212">photon</z:chebi> emission computed tomography was performed </plain></SENT>
<SENT sid="3" pm="."><plain>Immunostaining of caspase-3 (<z:mpath ids='MPATH_3'>apoptosis</z:mpath>), survivin (antiapoptosis), and LC3-II (autophagy marker) was also performed </plain></SENT>
<SENT sid="4" pm="."><plain>Different dynamics of (99m)Tc-(CO)₃ His-ann A5 uptake were observed in this <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e>, in response to a single dose of three different chemotherapeutics (5-FU, irinotecan, and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>) </plain></SENT>
<SENT sid="5" pm="."><plain>Bevacizumab-treated mice showed no increased uptake of the radiotracer, and a peak of (99m)Tc-(CO)₃ His-ann A5 uptake in panitumumab-treated mice was observed 24 hours posttreatment, as confirmed by caspase-3 immunostaining </plain></SENT>
<SENT sid="6" pm="."><plain>For irinotecan-, <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-, and bevacizumab-treated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, a significant correlation was established between the radiotracer uptake and caspase-3 immunostaining (r  =  .8, p &lt; .05; r  =  .9, p &lt; .001; r  =  .9, p &lt; .001, respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>For 5-FU- and panitumumab-treated mice, the correlation coefficients were r  =  .7 (p  =  .18) and r  =  .7 (p  =  .19), respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Optimal timing of annexin A5 imaging after the start of different treatments in the Colo205 model was determined </plain></SENT>
</text></document>